SEARCH:   Advanced

Blood, 15 June 2008, Vol. 111, No. 12, pp. 5530-5536. Prepublished online as a Blood First Edition Paper on April 14, 2008; DOI 10.1182/blood-2008-01-136242. This Article Full Text Full Text (PDF) All Versions of this Article: blood-2008-01-136242v1 111/12/5530    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via CrossRef Google Scholar Articles by Khouri, I. F. Articles by Champlin, R. E. PubMed PubMed Citation Articles by Khouri, I. F. Articles by Champlin, R. E. Related Collections Transplantation Free Research Articles Clinical Trials and Observations Neoplasia Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL TRIALS AND OBSERVATIONS Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab Issa F. Khouri1, Peter McLaughlin2, Rima M. Saliba1, Chitra Hosing1, Martin Korbling1, Ming S. Lee3, L. Jeffrey Medeiros3, Luis Fayad2, Felipe Samaniego2, Amin Alousi1, Paolo Anderlini1, Daniel Couriel1, Marcos de Lima1, Sergio Giralt1, Sattva S. Neelapu2, Naoto T. Ueno1, Barry I. Samuels4, Fredrick Hagemeister2, Larry W. Kwak2, and Richard E. Champlin1 Departments of1 Stem Cell Transplantation and Cellular Therapy, 2 Lymphoma and Myeloma 3 Hematopathology, and 4 Diagnostic Radiology, The University of Texas M. D. Anderson Cancer Center, Houston Nonmyeloablative stem cell transplantation in patients with follicular lymphoma has been designed to exploit the graft-versus-lymphoma immunity. The long-term effectiveness and toxicity of this strategy, however, is unknown. In this prospective study, we analyzed our 8-year experience. Patients received a conditioning regimen of fludarabine (30 mg/m2 daily for 3 days), cyclophosphamide (750 mg/m2 daily for 3 days), and rituximab (375 mg/m2 for 1 day plus 1000 mg/m2 for 3 days). They were then given an infusion of human leukocyte antigen-matched hematopoietic cells from related (n = 45) or unrelated donors (n = 2). Tacrolimus and methotrexate were used for graft-versus-host disease (GVHD) prophylaxis. Forty-seven patients were included. All patients experienced complete remission, with only 2 relapses. With a median follow-up time of 60 months (range, 19-94), the estimated survival and progression-free survival rates were 85% and 83%, respectively. All 18 patients who were tested and had evidence of JH/bcl-2 fusion transcripts in the bone marrow at study entry experienced continuous molecular remission. The incidence of grade 2-IV acute GVHD was 11%. Only 5 patients were still undergoing immunosuppressive therapy at the time of last follow-up. We believe that the described results are a step forward toward developing a curative strategy for recurrent follicular lymphoma. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

	Blood Online is supported in part by Genentech BioOncology and Biogen Idec
	Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020